The cancer care teams at Ascension Providence Cancer Center in Southfield are offering a new clinical safety trial that could provide hope to some cancer patients who are relapsed or resistant after two lines of therapy.
The hospital’s experts have become certified in Chimeric Antigen Receptor T-cell therapy, a clinical safety trial for patients with relapsed and refractory non-Hodgkin lymphoma.
CAR-T cell therapy is a form of immunotherapy that uses altered T-cells to attack and destroy cancer cells. The process involves removing, modifying, and returning white blood cells into the bloodstream. This enables the white blood cells to seek out the patient’s cancer cells and destroy them.
“This is a revolutionary breakthrough in the fight against cancer. This treatment process allows the immune system to treat cancer cells like they are germs,” says Dr. Howard Terebelo, program director at Ascension Providence Cancer Center and leader of the clinical safety trial. “We are excited to offer this unique CAR-T cell therapy, which is administered in the outpatient setting, allowing the patient to remain at home without required hospitalization. We were approved to conduct this trial because of our dedicated, advanced expertise in cancer care services.”
Ascension Providence Cancer Center care teams are looking for participants with aggressive B-cell non-Hodgkin lymphoma who are relapsed or resistant after two lines of therapy. Participants will receive CAR-T cell therapy over several weeks and be periodically assessed over two years for safety, disease response, body response, quality of life, and survival.
More information on the study can be found here by searching this number: NCT03744676. Those interested in participating can call (248) 465-5449 to determine eligibility.
Ascension operates 2,600 sites of care in 20 states and the District of Columbia, including 16 hospitals and hundreds of related facilities in Michigan.
